Company Overview
i-Lumen is advancing a non-invasive, physician-delivered therapy designed to restore vision in Dry-AMD patients, with clinical data demonstrating meaningful improvement. Operating in a large, underserved market, the company is positioned for near-term value inflection through its pivotal trial and planned FDA pathway.
What Differentiates i-Lumen
• Demonstrated Clinical Results — Patients showed meaningful vision improvement with sustained outcomes
• Non-Invasive Approach — Physician-delivered therapy designed to restore, not just preserve, vision
• Large Market Opportunity — 200M+ patients globally, with significant unmet need
• Strategic Positioning — Strong acquisition precedent in ophthalmology, including recent $850M transaction
• Active Raise — Currently raising a $35M Series B, with $18M already committed
